Tumor microenvironment has been known to inhibit immune responses. Many immune checkpoint inhibitors are now being tested for targeting various cancers. Instead of infusing antibody, we plan to infuse antibody-producing T cells (IgT) based on tumor surface antigen guided CAR-Tcells. EGFRvIII is an attractive target for GBM CAR-T therapy. Combination of EGFRviii or other GBM-specific CAR-T and IgT strategy, the CAR-IgT cells could target both the tumor cells and the tumor microenvironment.